Corcept Therapeutics Soars in Q1 2025, Hypercortisolism & Oncology Breakthroughs

Corcept Therapeutics Q1 2025 earnings show a 7% revenue increase to $157.2 million, with full-year guidance of $900-950 million. Despite a dip in net income, cash on hand is at $570.8 million, and they bought back $43 million in stock. Korlyms hypercortisolism treatments are booming, with record-breaking tablet shipments and a growing sales team. Relacorilants NDA is under FDA review, and oncology trials are showing promising results, positioning Corcept as a leader in cortisol modulation. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/faf14ec59480fa95